Chai Discovery Deal History & Licensing Activity
Chai Discovery is a life sciences. Over the past three years, Chai Discovery has been involved in 2 licensing and acquisition transactions, with a primary focus on Antibodies (2 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Antibodies
Focus Area
Other
Chai Discovery Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Chai Discovery in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Undisclosed | Novartis | Antibodies | Discovery | collaboration | Jul 14, 2026 |
| cancer-cell-surface target program | Amgen | Other | Discovery | license | Jan 7, 2026 |
Chai Discovery Pipeline Focus
Therapeutic areas and modalities where Chai Discovery is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Chai Discovery's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Chai Discovery Licensing & Deal Activity
Chai Discovery is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Chai Discovery ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Chai Discovery include Other (2 deals and trials), and Oncology (2 deals and trials). In terms of modality, Chai Discovery has shown particular interest in antibodies, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Chai Discovery and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Chai Discovery's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.